References
- Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Petrson C, Seveus L, Trulson A Eosinophil cationic protein (ECP): Molecular and biological properties and use of ECP as a marker of eosinophil activation in disease. Clin Exper Allergy 1999; 29:1172–1186.
- Moneret-Vautrin DA. Le dosage de la protéine cationique des éosinophiles est-il un marqueur utile pour l’interniste? Revue Méd Interne 2006; 27:679–683.
- McLaren DJ, Mckean JR, Olsson I, Venge P, Kay AB. Morphological studies on the killing of schistosomula of Schistosoma Mansoni by eosinophil and neutrophil cationic proteins in vitro. Parasite Immunol 1981; 3:359–373.
- Lehrer RI, Szklarez D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Anti-bacterial properties of eosinophil major basic protein (MBP) and eosinophil cationic protein (ECP). J Immunol 1989; 142:4428–4434.
- Chang HT, Kao YL, Wu CM, Fan TC, Lai YK, Huang KL, Chang YS, Tsai JJ, Chang MD. Signal peptide of eosinophil cationic protein upregulates transforming growth factor-alpha expression in human cells. J Cell Biochem 2007; 100:1266–1275.
- Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Rev 1998; 26:3358–3363.
- Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic levels in induced sputum correlate with the severity of bronchial asthma. Chest 1997; 112:1241–1127.
- Vatrella A, Ponticiello A, Parrella R. Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma. Allergy 1996; 51:547–555.
- Lemiere C, Pizzichini MM, Balkisson R, Clelland L. Diagnosing occupational asthma: Use of induced sputum. Eur Respir J 1999; 13:482–488.
- Shijubo N, Shigehara K, Hirasawa M, Inuzuka M, Abe S. Eosinophilic cationic protein in chronic eosinophilic pneumonia and eosinophilic granuloma. Chest 1994; 106:1481–1486.
- Fujimoto K, Kubo K, Yamaguchi S, Honda T, Matzsuzawa Y. Eosinophil activation in patients with pulmonary fibrosis. Chest 1995; 108:48–54.
- Taniguchi H, Katoh S, Kadota J, Matsubara Y, Fukushima K, Mukae H, Matsukura S, Kohno S. Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease. Eur Respir J 2000; 16:959–964.
- Denburg JA, Keith PK. Eosinophil progenitors in airway disease: Clinical implications. Chest 2008; 134:1037–1043.
- Sturm EM, Schratl P, Schuligoi R, Konya V, Sturm GJ, Lippe IT, Peskar BA, Heinemann A. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol 2008; 181:7273–7283.
- Lieberman P. Objective measures of asthma control: Sputum eosinophils, nitric oxide, and other inflammatory mediators. Allergy Asthma Proc 2007; 28:510–513.
- Ahmad Al, Obaidi AH, Mohamed Al, Samarai AG, Yahya Al, Samarai AK, Al Janabi JM. The predictive value of IgE as biomarker in asthma. J Asthma 2008; 45:654–663.
- Birring SS, Berry M, Brightling CE, Pavord ID. Eosinophilic bronchitis: Clinical features, management and pathogenesis. Am J Respir Med 2003; 2:169–173.